Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE FORTE versus PRED MILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE FORTE versus PRED MILD.
INFLAMASE FORTE vs PRED MILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Prednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2 and reduction of inflammatory mediators such as prostaglandins and leukotrienes.
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
1 to 2 drops in the affected eye(s) every hour during the day and every 2 hours at night until a favorable response is obtained, then reduce to 1 drop every 4 hours, and later to 1 drop 3 to 4 times daily as needed to control symptoms.
None Documented
None Documented
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
The terminal elimination half-life of prednisolone is approximately 2.1-3.5 hours. Clinically, this short half-life supports once-daily dosing for many conditions, with minimal accumulation upon repeated administration.
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Prednisolone is primarily excreted renally, with approximately 70-80% of the dose eliminated as metabolites in urine (including glucuronides and sulfates) and less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 20% of the dose.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid